| Literature DB >> 30784609 |
Abstract
Erythropoietin (EPO) is a 34kD pleiotropic cytokine that was first identified as being essential for red blood cell (RBC) production. It is now recognized however that EPO is produced by many tissues. It plays a key role in the modulation of the response to injury, inflammation, and tissue hypoxia via the inhibition of apoptosis. Large clinical trials in the critically ill failed to demonstrate a role for EPO as an RBC transfusion sparing agent; however, improved clinical outcomes, attributable to EPO role in tissue protection are observed in critically ill trauma patients. Further research to confirm or refute these observations is required. CrownEntities:
Keywords: Critical illness; Erythropoietin; Red blood cell transfusion; Trauma
Mesh:
Substances:
Year: 2019 PMID: 30784609 DOI: 10.1016/j.ccc.2018.11.015
Source DB: PubMed Journal: Crit Care Clin ISSN: 0749-0704 Impact factor: 3.598